December 01, 2004

Glaxo Smithkline working on new schizophrenia drug

UK drug major GlaxoSmithKline has provided an update on its drug in development to treat schizophrenia.

Talnetant, an NK3 antagonist, is being evaluated by GSK for schizophrenia. A Phase II trial is underway with a new formulation of the drug that permits higher dosing, and data are expected during next year. The agent may also provide cognitive benefits to schizophrenic patients.


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required